MedTrace Logo

Astaxanthin Formulation Bioavailability

NCT02397811 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-08-09

No results posted yet for this study

Summary

Human crossover pharmacokinetic study involving 12 subjects to determine the relative bioavailability of astaxanthin in six commercially available oral formulations.

Conditions

  • Bioavailability of Astaxanthin Formulations

Interventions

DIETARY_SUPPLEMENT

Enteric Coated Softgels

Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose

DIETARY_SUPPLEMENT

Liposomal astaxanthin

Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 3.66 grams per dose

DIETARY_SUPPLEMENT

Standard Softgel

Standard softgel containing 4 mg astaxanthin per softgel. 3 softgels per dose

DIETARY_SUPPLEMENT

Astaxanthin Water Soluble Emulsion

Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose

DIETARY_SUPPLEMENT

Astaxanthin Water Dispersible Powder

Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose

DIETARY_SUPPLEMENT

Standard Softgel with Astaxanthin Gel

Standard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 soft gels per dose

Sponsors & Collaborators

  • University of South Florida

    collaborator OTHER

  • Cyanotech Corporation

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02397811 on ClinicalTrials.gov